BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33586456)

  • 1. Influence of
    Zhang X; Liu C; Zhou S; Xie R; He X; Wang Z; Yi H; Shu Y; Wang Z; Hu K; Ma L; Cui Y; Zhao X; Xiang J
    Pharmacogenomics; 2021 Mar; 22(4):213-223. PubMed ID: 33586456
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
    Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
    J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.
    Koller D; Belmonte C; Lubomirov R; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Carcas A; Wojnicz A; Abad-Santos F
    J Psychopharmacol; 2018 Nov; 32(11):1212-1222. PubMed ID: 30251598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
    Kubo M; Koue T; Maune H; Fukuda T; Azuma J
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):358-66. PubMed ID: 17965519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.
    Koller D; Belmonte C; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):236-246. PubMed ID: 31520576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
    Hendset M; Molden E; Knape M; Hermann M
    Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of aripiprazole in healthy Korean subjects.
    Jeon JY; Chae SW; Kim MG
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):293-304. PubMed ID: 26902506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
    Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
    Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
    Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
    J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
    Guo L; Wang S; Wan Z; Ni S; Xu B; Zhao X; Liu L
    J Clin Pharm Ther; 2020 Aug; 45(4):632-637. PubMed ID: 32379356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
    Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.